Enovis (NYSE:ENOV – Get Free Report) and Teleflex (NYSE:TFX – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.
Valuation and Earnings
This table compares Enovis and Teleflex”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enovis | $2.25 billion | 0.48 | -$1.18 billion | ($19.26) | -0.97 |
| Teleflex | $1.99 billion | 2.72 | -$905.64 million | ($23.29) | -5.50 |
Profitability
This table compares Enovis and Teleflex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enovis | -47.96% | 12.03% | 4.91% |
| Teleflex | -39.67% | 11.93% | 5.44% |
Insider and Institutional Ownership
98.5% of Enovis shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 0.7% of Teleflex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Enovis has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Enovis and Teleflex, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enovis | 1 | 1 | 10 | 0 | 2.75 |
| Teleflex | 1 | 6 | 4 | 1 | 2.42 |
Enovis presently has a consensus target price of $40.38, suggesting a potential upside of 116.02%. Teleflex has a consensus target price of $152.90, suggesting a potential upside of 19.46%. Given Enovis’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Enovis is more favorable than Teleflex.
Summary
Enovis beats Teleflex on 10 of the 15 factors compared between the two stocks.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
About Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
